Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nathan Constantine-Cooke

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Biometrical Journal. Biometrische Zeitschrift|February 13, 2024
A review on statistical and machine learning competing risks methodsKarla Monterrubio-Gómez, Nathan Constantine-Cooke, Catalina A Vallejos
Therapeutic Advances in Gastroenterology|January 6, 2022
Real-world experience with tofacitinib in ulcerative colitis: a systematic review and meta-analysisLaura A Lucaciu, Nathan Constantine-Cooke, Nikolas Plevris, et al.
Frontline Gastroenterology|June 21, 2024
Real-world effectiveness of upadacitinib in Crohn's disease: a UK multicentre retrospective cohort studyAlexander Thomas Elford, Maria Bishara, Nikolas Plevris, et al.
Journal of Crohn'S & Colitis|December 9, 2023
Real-world Cohort Study on the Effectiveness and Safety of Filgotinib Use in Ulcerative ColitisBeatriz Gros, Mairi Goodall, Nik Plevris, et al.
Journal of Crohn'S & Colitis|December 11, 2024
Tofacitinib versus Vedolizumab Among Bio-naïve Patients with Ulcerative Colitis: A Real-World Propensity-Weighted ComparisonBeatriz Gros, Nathan Constantine-Cooke, Jake Kennedy, et al.
United European Gastroenterology Journal|February 21, 2023
Multiple infliximab biosimilar switches appear to be safe and effective in a real-world inflammatory bowel disease cohortBeatriz Gros, Nikolas Plevris, Nathan Constantine-Cooke, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 2, 2023
Longitudinal Fecal Calprotectin Profiles Characterize Disease Course Heterogeneity in Crohn's DiseaseNathan Constantine-Cooke, Karla Monterrubio-Gómez, Nikolas Plevris, et al.
Therapeutic Advances in Gastroenterology|August 1, 2024
Long-term outcomes and predictors of vedolizumab persistence in ulcerative colitisBeatriz Gros, Hannah Ross, Maureen Nwabueze, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 31, 2025
Large-scale clustering of longitudinal fecal calprotectin and C-reactive protein profiles in inflammatory bowel diseaseNathan Constantine-Cooke, Marie Vibeke Vestergaard, Nikolas Plevris, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|October 25, 2022
Rates, predictive factors and effectiveness of ustekinumab intensification to 4- or 6-weekly intervals in Crohn's diseaseLauranne A A P Derikx, Nikolas Plevris, Shanna Su, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Biometrical Journal. Biometrische Zeitschrift|February 13, 2024
A review on statistical and machine learning competing risks methodsKarla Monterrubio-Gómez, Nathan Constantine-Cooke, Catalina A Vallejos
Therapeutic Advances in Gastroenterology|January 6, 2022
Real-world experience with tofacitinib in ulcerative colitis: a systematic review and meta-analysisLaura A Lucaciu, Nathan Constantine-Cooke, Nikolas Plevris, et al.
Frontline Gastroenterology|June 21, 2024
Real-world effectiveness of upadacitinib in Crohn's disease: a UK multicentre retrospective cohort studyAlexander Thomas Elford, Maria Bishara, Nikolas Plevris, et al.
Journal of Crohn'S & Colitis|December 9, 2023
Real-world Cohort Study on the Effectiveness and Safety of Filgotinib Use in Ulcerative ColitisBeatriz Gros, Mairi Goodall, Nik Plevris, et al.
Journal of Crohn'S & Colitis|December 11, 2024
Tofacitinib versus Vedolizumab Among Bio-naïve Patients with Ulcerative Colitis: A Real-World Propensity-Weighted ComparisonBeatriz Gros, Nathan Constantine-Cooke, Jake Kennedy, et al.
United European Gastroenterology Journal|February 21, 2023
Multiple infliximab biosimilar switches appear to be safe and effective in a real-world inflammatory bowel disease cohortBeatriz Gros, Nikolas Plevris, Nathan Constantine-Cooke, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 2, 2023
Longitudinal Fecal Calprotectin Profiles Characterize Disease Course Heterogeneity in Crohn's DiseaseNathan Constantine-Cooke, Karla Monterrubio-Gómez, Nikolas Plevris, et al.
Therapeutic Advances in Gastroenterology|August 1, 2024
Long-term outcomes and predictors of vedolizumab persistence in ulcerative colitisBeatriz Gros, Hannah Ross, Maureen Nwabueze, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 31, 2025
Large-scale clustering of longitudinal fecal calprotectin and C-reactive protein profiles in inflammatory bowel diseaseNathan Constantine-Cooke, Marie Vibeke Vestergaard, Nikolas Plevris, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|October 25, 2022
Rates, predictive factors and effectiveness of ustekinumab intensification to 4- or 6-weekly intervals in Crohn's diseaseLauranne A A P Derikx, Nikolas Plevris, Shanna Su, et al.
Pageof 2